CompoAtlas

Joint Maintenance Pack

En vente sur le marché américain (selon le DSLD)

Wonder Laboratories, food supplement from the US market

Joint Maintenance Pack (Wonder Laboratories), a food supplement without a usable barcode in DSLD, is described by its US market label. If sold in France, it would be subject to 5 points of French or European regulation, detailed below. Doses of niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Wonder Laboratories
Barcode
Not provided or invalid in DSLD
Form
Tablet
One serving
1 packet
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Maltodextrin, Vegetable Cellulose, Gelatin, Vegetable Stearic Acid, Sodium Starch Glycolate, Silica, Vegetable Magnesium Stearate, Grape Seed Extract, Malic Acid, Turmeric, White Willow bark extract, Magnesium Silicate, BioPerine, Vanillin
Ingredient (as written, in English)CategoryPer serving
Vitamin CVitamin100 mg
NiacinVitamin100 mg
Vitamin B6Vitamin10 mg
Pantothenic AcidVitamin100 mg
CalciumMineral189 mg
MagnesiumMineral33 mg
ManganeseMineral2 mg
PotassiumMineral14 mg
Glucosamine SulfateOther substance150 mg
M.S.M.Other substance150 mg
Alfalfa (Medicago sativa)Plant100 mg
BetaineOther substance25 mg
Valerian root extract (Valeriana officinalis)Plant260 mg
Passion flower extract (Passiflora incarnata)Plant260 mg
GingerPlant550 mg
Hawthorn P.E.Plant180 mg
Licorice root extractPlant102 mg
Goldenseal P.E. (Hydrastis canadensis)Plant30 mg
Cascara Sagrada P.E. (Frangula purshiana)Plant197 mg
Shiitake MushroomOther30 mg
BurdockPlant30 mg
Buckthorn (Rhamnus cathartica)Plant30 mg
Cayenne (Capsicum annuum)Plant21 mg
Celery (Apium graveolens)Plant42 mg
DandelionPlant167 mg
Mexican Yam extractPlant11 mg

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Alfalfa
    Read the warning, when it applies and the studies cited

    ALFALFA - MEDICAGO SATIVA

    Route of administration: Oral

    Cautions and warnings

    Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners, birth control medication or hormone therapy (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 900 mg of Alfalfa dried herb top/leaf, per day.

    Do not use if you have a history of systemic lupus erythematosus (Brinker 2010; Barnes et al. 2007; Boon and Smith 2004).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Betaine
    Read the warning, when it applies and the studies cited

    BETAINE / BETAINE HYDROCHLORIDE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Applies to products containing Betaine hydrochloride (as a medicinal ingredient or as a source ingredient).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a peptic ulcer or excess stomach acid (RSC 2024; Hendler and Rorvik 2008).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 600 milligrams or more of Betaine or 780 milligrams or more of Betaine hydrochloride as a medicinal ingredient, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high cholesterol (Olthof et al. 2005; Swab et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 January 2026

  • Valerian root extract
    Read the warning, when it applies and the studies cited

    Valerian - VALERIANA OFFICINALIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 26 July 2024

  • Passion flower extract
    Read the warning, when it applies and the studies cited

    PASSIONFLOWER -PASSIFLORA INCARNATA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Sleep aid.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2014).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Goldenseal P.E.
    Read the warning, when it applies and the studies cited

    GOLDENSEAL - HYDRASTIS CANADENSIS - Buccal

    Cautions and warnings

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Ask a health care practitioner/health care provider/health care professional/ doctor/physician before use if you have a kidney or blood pressure disorder (Brinker 2010; Hoffmann 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes and al. 2007; Mills and Bone 2005; Boon and Smith 2004; Hoffmann 2003; Bradley 1992).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 March 2025

    GOLDENSEAL - HYDRASTIS CANADENSIS - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional before use if you have a kidney or blood pressure disorder (Brinker 2010; Hoffmann 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes and al. 2007; Mills and Bone 2005; Boon and Smith 2004; Hoffmann 2003; Bradley 1992).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 November 2024

  • Cascara Sagrada P.E.
    Read the warning, when it applies and the studies cited

    CASCARA SAGRADA - FRANGULA PURSHIANA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 May 2025

  • Cayenne
    Read the warning, when it applies and the studies cited

    CAYENNE - CAPSICUM ANNUUM Oral

    Cautions and warnings

    Condition of application: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Cautions and warnings

    Condition of application: All products.

    For external use only (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 March 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : Wonder Laboratories

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line